The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors

被引:28
|
作者
Pajarillo, Edward [1 ]
Rizor, Asha [1 ]
Lee, Jayden [2 ]
Aschner, Michael [3 ]
Lee, Eunsook [1 ]
机构
[1] Florida A&M Univ, Coll Pharm, Dept Pharmaceut Sci, Tallahassee, FL 32301 USA
[2] Boston Univ, Dept Speech Language & Hearing Sci, Boston, MA 02215 USA
[3] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE | 2019年 / 1865卷 / 08期
基金
美国国家卫生研究院;
关键词
alpha-Synuclein; LRRK2; Parkinson's disease; Manganese; Posttranslational modifications; REPEAT KINASE 2; N-TERMINAL ACETYLATION; IN-VITRO; DOPAMINERGIC NEURODEGENERATION; MITOCHONDRIAL DYSFUNCTION; DOMINANT PARKINSONISM; TYROSINE NITRATION; OXIDATIVE STRESS; SUBSTANTIA-NIGRA; 14-3-3; BINDING;
D O I
10.1016/j.bbadis.2018.11.017
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease (AD), and the most prevalent movement disorder. PD is characterized by dopaminergic neurodegeneration in the substantia nigra, but its etiology has yet to be established. Among several genetic variants contributing to PD pathogenesis, alpha-synuclein and leucine-rich repeat kinase (LRRK2) are widely associated with neuropathological phenotypes in familial and sporadic PD. alpha-Synuclein and LRRK2 found in Lewy bodies, a pathogenic hallmark of PD, are often posttranslationally modified. As posttranslational modifications (PTMs) are key processes in regulating the stability, localization, and function of proteins, PTMs have emerged as important modulators of alpha-synuclein and LRRK2 pathology. Aberrant PTMs altering phosphorylation, ubiquitination, nitration and truncation of these proteins promote PD pathogenesis, while other PTMs such as sumoylation may be protective. Although the causes of many aberrant PTMs are unknown, environmental risk factors may contribute to their aberrancy. Environmental toxicants such as rotenone and paraquat have been shown to interact with these proteins and promote their abnormal PTMs. Notably, manganese (Mn) exposure leads to a PD-like neurological disorder referred to as manganism-and induces pathogenic PTMs of alpha-synuclein and LRRK2. In this review, we highlight the role of PTMs of alpha-synuclein and LRRK2 in PD pathogenesis and discuss the impact of environmental risk factors on their aberrancy.
引用
收藏
页码:1992 / 2000
页数:9
相关论文
共 50 条
  • [21] LRRK2 and Lipid Pathways: Implications for Parkinson's Disease
    Galper, Jasmin
    Kim, Woojin S.
    Dzamko, Nicolas
    BIOMOLECULES, 2022, 12 (11)
  • [22] LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease
    Alegre-Abarrategui, J.
    Ansorge, O.
    Esiri, M.
    Wade-Martins, R.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2008, 34 (03) : 272 - 283
  • [23] THE COMPLEX RELATIONSHIPS BETWEEN MICROGLIA, ALPHA-SYNUCLEIN, AND LRRK2 IN PARKINSON'S DISEASE
    Schapansky, J.
    Nardozzi, J. D.
    Lavoie, M. J.
    NEUROSCIENCE, 2015, 302 : 74 - 88
  • [24] Mutations in LRRK2 as a cause of Parkinson's disease
    Giasson, Benoit I.
    Van Deerlin, Vivianna M.
    NEUROSIGNALS, 2008, 16 (01) : 99 - 105
  • [25] LRRK2 activation in idiopathic Parkinson's disease
    Di Maio, Roberto
    Hoffman, Eric K.
    Rocha, Emily M.
    Keeney, Matthew T.
    Sanders, Laurie H.
    De Miranda, Briana R.
    Zharikov, Alevtina
    Van Laar, Amber
    Stepan, Antonia F.
    Lanz, Thomas A.
    Kofler, Julia K.
    Burton, Edward A.
    Alessi, Dario R.
    Hastings, Teresa G.
    Greenamyre, J. Timothy
    SCIENCE TRANSLATIONAL MEDICINE, 2018, 10 (451)
  • [26] The role of LRRK2 in the periphery: link with Parkinson's disease and inflammatory diseases
    Tsafaras, George
    Baekelandt, Veerle
    NEUROBIOLOGY OF DISEASE, 2022, 172
  • [27] LRRK2, a puzzling protein: Insights into Parkinson's disease pathogenesis
    Esteves, A. Raquel
    Swerdlow, Russell H.
    Cardoso, Sandra M.
    EXPERIMENTAL NEUROLOGY, 2014, 261 : 206 - 216
  • [28] Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade
    Thakur, Gunjan
    Kumar, Vikas
    Lee, Keun Woo
    Won, Chungkil
    GENES, 2022, 13 (08)
  • [29] LRRK2 pathobiology in Parkinson's disease
    Martin, Ian
    Kim, Jungwoo Wren
    Dawson, Valina L.
    Dawson, Ted M.
    JOURNAL OF NEUROCHEMISTRY, 2014, 131 (05) : 554 - 565
  • [30] Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson's disease
    Gonzalez-Hunt, C. P.
    Thacker, E. A.
    Toste, C. M.
    Boularand, S.
    Deprets, S.
    Dubois, L.
    Sanders, L. H.
    SCIENTIFIC REPORTS, 2020, 10 (01)